For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is ABIOMED one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

ABIOMED is a member of the Medical sector. This group includes 764 individual stocks and currently holds a Zacks Sector Rank of #9. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ABMD is currently sporting a Zacks Rank of #1 (Strong Buy).

Over the past 90 days, the Zacks Consensus Estimate for ABMD's full-year earnings has moved 8.69% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

Our latest available data shows that ABMD has returned about 85.36% since the start of the calendar year. At the same time, Medical stocks have lost an average of 3.74%. This shows that ABIOMED is outperforming its peers so far this year.

Breaking things down more, ABMD is a member of the Medical - Instruments industry, which includes 88 individual companies and currently sits at #161 in the Zacks Industry Rank. Stocks in this group have lost about 8.83% so far this year, so ABMD is performing better this group in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track ABMD. The stock will be looking to continue its solid performance.